Cytoreductive surgery is feasible in patients with limited regional platinum-resistant recurrent ovarian cancer.

ABSTRACT:

Introduction

To evaluate the efficacy of cytoreductive surgery versus chemotherapy for the treatment of limited regional, platinum-resistant ovarian cancer (PROC).

Materials and methods

The clinical records of all patients with PROC treated in our center between March 2015 and March 2022 were retrospectively reviewed. We compared the oncology outcomes of patients who received cytoreduction or chemotherapy alone at relapse and presented information about postoperative adjuvant chemotherapy.

Results

Among 52 patients with limited regional recurrence, 40.4% (21/52) underwent cytoreduction because of platinum resistance, and 59.6% (31/52) received chemotherapy alone. No residual disease (R0) was achieved in 20 patients (95.2%). The severe morbidity rate within 30 days aft

SUBMITTER: Zou R 

PROVIDER: S-EPMC10688147 | biostudies-literature | 2023 Nov

REPOSITORIES: biostudies-literature